Alessandra Giorgetti

Alessandra Giorgetti

Auto-generated profile, based on publicly available information

Alessandra Giorgetti

Regenerative Medicine Program, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2011 in Nature
Verified
Journal Article
Open access
PDF file
AGAthurva Gore
Athurva Gore
ZLZhe Li
Zhe Li
HFHo-Lim Fung
Ho-Lim Fung
JYJessica E. Young
Jessica E. Young
SASuneet Agarwal
Suneet Agarwal
KZKun Zhang
Kun Zhang
Defined transcription factors can induce epigenetic reprogramming of adult mammalian cells into induced pluripotent stem cells. Although DNA factors are integrated during some reprogramming methods, it is unknown whether the genome remains unchanged at the single nucleotide level. Here we show that 22 human induced pluripotent stem (hiPS) cell lines reprogrammed using five different methods each contained an average of five protein-coding point mutations in the regions sampled (an estimated six protein-coding point mutations per exome). The majority of these mutations were non-synonymous, nonsense or splice variants, and were enriched in genes mutated or having causative effects in cancers. At least half of these reprogramming-associated mutations pre-existed in fibroblast progenitors at low frequencies, whereas the rest occurred during or after reprogramming. Thus, hiPS cells acquire genetic modifications in addition to epigenetic modifications. Extensive genetic screening should become a standard procedure to ensure hiPS cell safety before clinical use.

1 October 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
AGAlessandra Giorgetti
Alessandra Giorgetti
NMNuria Montserrat
Nuria Montserrat
Trond AasenTrond Aasen
Trond Aasen
FGFederico Gonzalez
Federico Gonzalez
IRIgnacio Rodríguez-Pizà
Ignacio Rodríguez-Pizà
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte

26 July 2011 in Stem Cells
Verified
Journal Article
Closed access
PDF file
CEC. Eguizabal
C. Eguizabal
NMN. Montserrat
N. Montserrat
RVRita Vassena
Rita Vassena
MBM. Barragan
M. Barragan
EGE. Garreta
E. Garreta
JBJ. C. Izpisua Belmonte
J. C. Izpisua Belmonte

18 September 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SRSergio Ruiz
Sergio Ruiz
DDDinh Diep
Dinh Diep
AGAthurva Gore
Athurva Gore
APAthanasia D. Panopoulos
Athanasia D. Panopoulos
NMNuria Montserrat
Nuria Montserrat
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte
Generation of human induced pluripotent stem cells (hiPSCs) by the expression of specific transcription factors depends on successful epigenetic reprogramming to a pluripotent state. Although hiPSCs and human embryonic stem cells (hESCs) display a similar epigenome, recent reports demonstrated the persistence of specific epigenetic marks from the somatic cell type of origin and aberrant methylation patterns in hiPSCs. However, it remains unknown whether the use of different somatic cell sources, encompassing variable levels of selection pressure during reprogramming, influences the level of epigenetic aberrations in hiPSCs. In this work, we characterized the epigenomic integrity of 17 hiPSC lines derived from six different cell types with varied reprogramming efficiencies. We demonstrate that epigenetic aberrations are a general feature of the hiPSC state and are independent of the somatic cell source. Interestingly, we observe that the reprogramming efficiency of somatic cell lines inversely correlates with the amount of methylation change needed to acquire pluripotency. Additionally, we determine that both shared and line-specific epigenetic aberrations in hiPSCs can directly translate into changes in gene expression in both the pluripotent and differentiated states. Significantly, our analysis of different hiPSC lines from multiple cell types of origin allow us to identify a reprogramming-specific epigenetic signature comprised of nine aberrantly methylated genes that is able to segregate hESC and hiPSC lines regardless of the somatic cell source or differentiation state.

1 April 2010 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
AGAlessandra Giorgetti
Alessandra Giorgetti
NMNuria Montserrat
Nuria Montserrat
IRIgnacio Rodriguez-Piza
Ignacio Rodriguez-Piza
CACarmen Azqueta
Carmen Azqueta
AVAnna Veiga
Anna Veiga
JBJuan Carlos Izpisúa Belmonte
Juan Carlos Izpisúa Belmonte

1 December 2003 in Blood
Verified
Journal Article
Closed access
PDF file
LCLinda A. Cairns
Linda A. Cairns
EMEmanuela Moroni
Emanuela Moroni
Elena LevantiniElena Levantini
Elena Levantini
AGAlessandra Giorgetti
Alessandra Giorgetti
FKFrancesca Gioia Klinger
Francesca Gioia Klinger
SOSergio Ottolenghi
Sergio Ottolenghi
The Kit (White) gene encodes the transmembrane receptor of stem cell factor/Kit ligand (KL) and is essential for the normal development/maintenance of pluripotent primordial germ cells (PGCs), hematopoietic stem cells (HSCs), melanoblasts, and some of their descendants. The molecular basis for the transcriptional regulation of Kit during development of these important cell types is unknown. We investigated Kit regulation in hematopoietic cells and PGCs. We identified 6 DNase I hypersensitive sites (HS1-HS6) within the promoter and first intron of the mouse Kit gene and developed mouse lines expressing transgenic green fluorescent protein (GFP) under the control of these regulatory elements. A construct driven by the Kit promoter and including all 6 HS sites is highly expressed during mouse development in Kit+ cells including PGCs and hematopoietic progenitors (erythroid blast-forming units and mixed colony-forming units). In contrast, the Kit promoter alone (comprising HS1) is sufficient to drive low-level GFP expression in PGCs, but unable to function in hematopoietic cells. Hematopoietic expression further requires the addition of the intronproximal HS2 fragment; HS2 also greatly potentiates the activity in PGCs. Thus, HS2 acts as an enhancer integrating transcriptional signals common to 2 developmentally unrelated stem cell/progenitor lineages. Optimal hematopoietic expression further requires HS3-HS6.